An Open-label Study of XEN1101 in Epilepsy
← catalyst calendarNCT05718817 · readout ≤ 2,446 d
Sponsored by Xenon Pharmaceuticals Inc. (industry) · XENE — their whole pipeline →. With Worldwide Clinical Trials.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
880estimated
Sites
151
Countries
Argentina, Australia, Austria +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-25 | actual | When the study began enrolling |
| Primary completion | Apr 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Focal Epilepsy
- Tonic-Clonic Seizures
Intervention
- Drug: XEN1101 — also filed as Azetukalner
Primary outcome
what the primary-completion date above is the date OFThe adverse events
measured From the start of treatment in the open-label extension (OLE) study through 8 weeks after the last dose.
Permalink · XENE's whole pipeline · Catalyst calendar · Every registered study · What changed